Literature DB >> 7524030

Extension of helix II of an HIV-1-directed hammerhead ribozyme with long antisense flanks does not alter kinetic parameters in vitro but causes loss of the inhibitory potential in living cells.

M Homann1, M Tabler, S Tzortzakaki, G Sczakiel.   

Abstract

When designed to cleave a target RNA in trans, the hammerhead ribozyme contains two antisense flanks which form helix I and helix III by pairing with the complementary target RNA. The sequences forming helix II are contained on the ribozyme strand and represent a major structural component of the hammerhead structure. In the case of an inhibitory 429 nucleotides long trans-ribozyme (2as-Rz12) which was directed against the 5'-leader/gag region of the human immunodeficiency virus type 1 (HIV-1), helix II was not pre-formed in the single-stranded molecule. Thus, major structural changes are necessary before cleavage can occur. To study whether pre-formation of helix II in the non-paired 2as-Rz12 RNA could influence the observed cleavage rate in vitro and its inhibitory activity on HIV-1 replication, we extended the 4 base pair helix II of 2as-Rz12 to 6, 10, 21, and 22 base pairs respectively. Limited RNase cleavage reactions performed in vitro at 37 degrees C and at physiological ion strength indicated that a helix II of the hammerhead domain was pre-formed when its length was at least six base pairs. This modification neither affected the association rate with target RNA nor the cleavage rate in vitro. In contrast to this, extension of helix II led to a significantly decreased inhibition of HIV-1 replication in human cells. Together with the finding of others that shortening of helix II to less than two base pairs reduces the catalytic activity in vitro, this observation indicates that the length of helix II in the naturally occurring RNAs with a hammerhead domain is already close or identical to the optimal length for catalytic activity in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524030      PMCID: PMC308395          DOI: 10.1093/nar/22.19.3951

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  36 in total

1.  Renaturation of complementary DNA strands mediated by purified mammalian heterogeneous nuclear ribonucleoprotein A1 protein: implications for a mechanism for rapid molecular assembly.

Authors:  B W Pontius; P Berg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Substrate sequence effects on "hammerhead" RNA catalytic efficiency.

Authors:  M J Fedor; O C Uhlenbeck
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

3.  Rapid renaturation of complementary DNA strands mediated by cationic detergents: a role for high-probability binding domains in enhancing the kinetics of molecular assembly processes.

Authors:  B W Pontius; P Berg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  Self-cleavage of virusoid RNA is performed by the proposed 55-nucleotide active site.

Authors:  A C Forster; R H Symons
Journal:  Cell       Date:  1987-07-03       Impact factor: 41.582

6.  In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1.

Authors:  K Rittner; C Burmester; G Sczakiel
Journal:  Nucleic Acids Res       Date:  1993-03-25       Impact factor: 16.971

7.  Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1.

Authors:  M Homann; S Tzortzakaki; K Rittner; G Sczakiel; M Tabler
Journal:  Nucleic Acids Res       Date:  1993-06-25       Impact factor: 16.971

8.  Expression of a chimeric ribozyme gene results in endonucleolytic cleavage of target mRNA and a concomitant reduction of gene expression in vivo.

Authors:  P Steinecke; T Herget; P H Schreier
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

9.  Cytoplasmic delivery of ribozymes leads to efficient reduction in alpha-lactalbumin mRNA levels in C127I mouse cells.

Authors:  P J L'Huillier; S R Davis; A R Bellamy
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

10.  RNA annealing activities in HeLa nuclei.

Authors:  D S Portman; G Dreyfuss
Journal:  EMBO J       Date:  1994-01-01       Impact factor: 11.598

View more
  14 in total

1.  Efficient and specific ribozyme-mediated reduction of bovine alpha-lactalbumin expression in double transgenic mice.

Authors:  P J L'Huillier; S Soulier; M G Stinnakre; L Lepourry; S R Davis; J C Mercier; J L Vilotte
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 2.  Hammerhead ribozyme kinetics.

Authors:  T K Stage-Zimmermann; O C Uhlenbeck
Journal:  RNA       Date:  1998-08       Impact factor: 4.942

Review 3.  Antiviral ribozymes. New jobs for ancient molecules.

Authors:  A Menke; G Hobom
Journal:  Mol Biotechnol       Date:  1997-08       Impact factor: 2.695

4.  Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase.

Authors:  H Kawasaki; J Ohkawa; N Tanishige; K Yoshinari; T Murata; K K Yokoyama; K Taira
Journal:  Nucleic Acids Res       Date:  1996-08-01       Impact factor: 16.971

Review 5.  Ribozymes. Their functions and strategies for their use.

Authors:  S A Gibson; E J Shillitoe
Journal:  Mol Biotechnol       Date:  1997-04       Impact factor: 2.695

6.  A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets.

Authors:  Edwin H Yau; Mark C Butler; Jack M Sullivan
Journal:  Exp Eye Res       Date:  2016-05-25       Impact factor: 3.467

7.  A comparison of the in vitro activity of DNA-armed and all-RNA hammerhead ribozymes.

Authors:  P Hendry; M J McCall
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

8.  Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes.

Authors:  M Zoumadakis; M Tabler
Journal:  Nucleic Acids Res       Date:  1995-04-11       Impact factor: 16.971

9.  Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy.

Authors:  Heba E Abdelmaksoud; Edwin H Yau; Michael Zuker; Jack M Sullivan
Journal:  Exp Eye Res       Date:  2008-12-06       Impact factor: 3.467

10.  A spermidine-induced conformational change of long-armed hammerhead ribozymes: ionic requirements for fast cleavage kinetics.

Authors:  C Hammann; R Hormes; G Sczakiel; M Tabler
Journal:  Nucleic Acids Res       Date:  1997-12-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.